Based on the key measurements obtained from GT Biopharma's financial statements, GT Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, GT Biopharma's Current Deferred Revenue is relatively stable compared to the past year. As of 01/31/2025, Net Tangible Assets is likely to grow to about 26.5 M, while Total Current Liabilities is likely to drop slightly above 6.9 M. Key indicators impacting GT Biopharma's financial strength include:
The financial analysis of GT Biopharma is a critical element in measuring its lifeblood. Investors should not minimize GT Biopharma's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(7.18 Million)
GTBP
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Change In Working Capital
Change To Inventory
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Change To Account Receivables
Total Cash From Financing Activities
Sale Purchase Of Stock
Change To Liabilities
Stock Based Compensation
Total Cashflows From Investing Activities
Net Borrowings
Change To Operating Activities
Change To Netincome
Investments
Issuance Of Capital Stock
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Common Stock
Accumulated Other Comprehensive Income
Non Current Liabilities Total
Short Long Term Debt Total
Short Term Debt
Other Assets
Long Term Debt
Preferred Stock Total Equity
Intangible Assets
Property Plant Equipment
Current Deferred Revenue
Good Will
Short Term Investments
Net Tangible Assets
Short Long Term Debt
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Minority Interest
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Net Interest Income
Interest Income
Probability Of Bankruptcy
Understanding current and past GT Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of GT Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in GT Biopharma's assets may result in an increase in income on the income statement.
GT Biopharma competes with Allarity Therapeutics, Virax Biolabs, Quoin Pharmaceuticals, Virpax Pharmaceuticals, and Revelation Biosciences. GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager fusion protein immune cell engager technology platform. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. GT Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what GT Biopharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining GT Biopharma's current stock value. Our valuation model uses many indicators to compare GT Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GT Biopharma competition to find correlations between indicators driving GT Biopharma's intrinsic value. More Info.
GT Biopharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, GT Biopharma's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value GT Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
GT Biopharma Systematic Risk
GT Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GT Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on GT Biopharma correlated with the market. If Beta is less than 0 GT Biopharma generally moves in the opposite direction as compared to the market. If GT Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GT Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GT Biopharma is generally in the same direction as the market. If Beta > 1 GT Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in GT Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GT Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of GT Biopharma growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of GT Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GT Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of GT Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing GTBP Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GT Biopharma's daily price indicators and compare them against related drivers.
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.